Sign inJoin waitlistJoin the waitlist

Lydia Usha

Director, Rush Inherited Susceptibility to Cancer (RISC) Center · Rush University Medical Center

Credentials: · · ·

History

Rush Inherited Susceptibility to Cancer (RISC) Center · Rush University Medical Center
Present
Rush University Medical Center
Present

Medical Oncology
1985–1987
Internal Medicine
1982–1985
Saint Petersburg Medico-Social Institute
1978–1982

Research

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Journal of Clinical Oncology · 2020 · 337 citations
Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
Advances in Radiation Oncology · 2019 · 57 citations
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in…
Gynecologic Oncology · 2011 · First of 10 authors · Corresponding · 41 citations

Melody Cobleigh
9 papers
Ruta Rao
6 papers
RG
Ritu Ghai
4 papers
JR
Jacob Rotmensch
3 papers
Rachel Mitchell
3 papers · 2 as a fellow
Summer Dewdney
3 papers · 1 as a fellow
Timothy Kuzel
3 papers
BT
Bita Tabesh
2 papers
Claudia Perez
2 papers
Dian Wang
2 papers
EE
Elizabeth Elliott
2 papers · 2 as a fellow
Jamile Shammo
2 papers

Clinical trials

A Study of Serum Folate Levels in Patients Treated With Olaparib
Principal investigator · Completed · Phase 4
Rush University Medical Center
2020–2025
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Study chair · Completed · Phase 2
Gynecologic Oncology Group
2006
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Molecular Genetics Studies of Cancer Patients and Their Relatives
Site PI · Recruiting
City of Hope Medical Center
1997–2033